OOppenheimer MMarvell · MRVL

Oppenheimer Raises Marvell Price Target to $200

May 20, 2026· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$200
Previous
$170
Implied upside
+13%

Oppenheimer analyst Rick Shafer raised the price target on Marvell Technology (NASDAQ: MRVL) to $200.00 (from $170.00) while maintaining an Outperform rating.

“MRVL reports Wednesday (5/27). We see upside F1Q (Apr.) results and F2Q (Jul.) outlook led by AI networking and custom ASIC as CSPs continue to scale DC builds.

Top four CSP spend expected >$710B this year (vs. Jan 1 expects near $480B), providing robust order visibility for critical infrastructure providers like MRVL.

Mgmt. sees $11B/$15B+ top line in CY26/CY27, respectively. We view these targets as a floor, with material upside possible as advanced wafer capacity improves.

By our work, demand supports CY27 revenue closer to $20B. Lead times stretched 9–12 months.

Optics CAGR 50% the past five years, poised to grow >60% this year led by MRVL’s full optics platform (PAM, DCI, switching, etc). Custom ASIC up >30% this year to $2B led by AWS (Trainium).

Second large AI ASIC (MSFT Maia, $2B PO) begins ramp late this year.

MRVL’s broad AI ASIC/ networking portfolio drives structural growth through decade-end. Reiterate Outperform. Target $200 (prior $170).”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.